Jubilant Ingrevia's specialty pivot lifted EBITDA margin from 9% to 15% (interview)
CEO Deepak Jain moved half the portfolio out of commodities; specialty and nutrition now drive 90% of EBITDA and Q1 FY26 profit rose 54% (self-reported).
What was changed
In an exclusive ET Manufacturing interview, Jubilant Ingrevia CEO and MD Deepak Jain credited a two-year transformation for a quarter in which chemicals peers struggled: Q1 FY26 net profit rose 54% year-on-year to ₹75 crore and EBITDA 29% to ₹153 crore on flat revenue of ₹1,038 crore — all figures self-reported in the interview. Two and a half years ago, nearly half the business was commoditised, he said; today specialty chemicals and nutrition contribute 90 per cent of EBITDA. “We've pivoted from being a commodity-heavy chemicals firm to a speciality-focused enterprise,” Jain said.
Under the 'Pinnacle' strategy, Jain — who joined from Bain & Company in 2023 — directed over ₹2,000 crore of investment across three years into Pyridine and Diketene derivatives, CDMO and nutrition ingredients. EBITDA margin reached 15%, up from 9% six quarters earlier; specialty alone clocks a 27% margin, with a target near 20% overall. The Lean 2.0 cost programme saved over ₹100 crore last year, a quarter of this year's target captured in Q1.
The CDMO pipeline is expanding: in pharma, the opportunity funnel doubled across the US, EU and Japan; in agrochemicals, a dedicated plant is under construction at Bharuch against a $300 million, five-year CDMO contract; and the company counts over 12 active semiconductor CDMO opportunities — upstream chemicals now, 'a 10-year play,' in Jain's words.
Why it worked
Commodity lines like acetyls exposed the company to price erosion, while specialty derivatives carry 27% EBITDA margins.
₹2,000 crore aimed at pyridine, diketene, CDMO and nutrition platforms shifted the EBITDA mix faster than volume growth could.
Lean 2.0 savings of over ₹100 crore a year offset commodity price erosion while the mix shift compounded margins.
What can be applied
In a flat-price commodity business, mix is the only margin: shifting revenue share to specialty platforms re-rates the whole P&L without waiting for volumes.
Aftermath
Jain targets overall EBITDA margin near 20% over the next few years; the Bharuch agrochemical CDMO plant is under construction against the $300 million five-year contract, and semiconductor CDMO work is being built as a decade-long platform.